Search -

Displaying 121 - 140 of 225

Sort: Relevancy | Date

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Conference News ADA 2023

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

L.A. McKeown

June 28, 2023

News Daily News

US Athlete’s Death Highlights Risk of Hypertensive Disorders of Pregnancy

Michael O'Riordan

June 19, 2023

News Opinion CV Team Dispatch

June 2023 News Roundup

L.A. McKeown

June 01, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Daily News

In COVID-19 Patients, Vaccination Linked to Lower MACE Risk

Michael O'Riordan

February 22, 2023

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

News Opinion CV Team Dispatch

October 2022 News Roundup

L.A. McKeown

October 01, 2022

News Daily News

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

Shelley Wood

August 23, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Advertisement

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

US Athlete’s Death Highlights Risk of Hypertensive Disorders of Pregnancy

June 2023 News Roundup

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

In COVID-19 Patients, Vaccination Linked to Lower MACE Risk

Longer-Term ASCVD Risk Assessment Best for Younger Patients

January 2023 News Roundup

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 2022 News Roundup

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content